Table 1 The relation between the expression level of NORAD and clinicopathologic characteristics.
Clinicopathological data | No. of patients | NORAD/GAPDH expression | χ2 | P-value | |
|---|---|---|---|---|---|
n | Low | High | |||
Total | 56 | Â | Â | Â | Â |
FIGO stage | Â | Â | Â | Â | Â |
I & II stage | 46 | 20 (43.5%) | 26 (56.5%) | 4.38 | <0.05* |
III & IV stage | 10 | 8 (80%) | 2 (20%) | Â | Â |
Grade | Â | Â | Â | Â | Â |
Grade I | 36 | 13 (36.1%) | 23 (63.9%) | 5.45 | >0.05 |
Grade II | 6 | 5 (83.3%) | 1 (16.7%) | Â | Â |
Grade III | 5 | 3 (60%) | 2 (40%) | Â | Â |
ER | Â | Â | Â | Â | Â |
Positive | 51 | 24 (47.1%) | 27 (52.9%) | 1.41 | >0.05 |
Negative | 3 | 3 (100%) | 0 (0%) | Â | Â |
Histological type | Â | Â | Â | Â | Â |
Endometrioid | 48 | 22 (45.8%) | 26 (54.2%) | 1.31 | >0.05 |
Nonendometrioid | 8 | 6 (75%) | 2 (25%) | Â | Â |
Age | Â | Â | Â | Â | Â |
<55 years | 16 | 4 (25%) | 12 (75%) | 6.45 | <0.05* |
≥55 years | 40 | 25 (62.5%) | 15 (37.5%) |  |  |
Myometrial invasion | Â | Â | Â | Â | Â |
<1/2 | 43 | 19 (44.2%) | 24 (55.8%) | 1.9 | >0.05 |
≥1/2 | 12 | 8 (66.7%) | 4 (33.3%) |  |  |
Lymph node metastasis | Â | Â | Â | Â | Â |
No | 50 | 24 (48%) | 26 (52%) | 0.19 | >0.05 |
Yes | 6 | 4 (66.7%) | 2 (33.3%) | Â | Â |
